1.
Kollef M.N., Sherman G., Ward S., Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-74.
2.
Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10.
3.
Moore R.D., Lietman P.S., Smith C.R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-9.
4.
Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-81.
5.
Ferrara A., Grassi G., Grassi F.A., Piccioni P.D., Gialdroni Grassi G. Bactericidal activity of meropenem and interactions with other antibiotics. J Antimicrob Chemother 1989; 24 (Suppl. A):239-50.
6.
Martinez F.F., Caminero M.M., Izquierdo J.I., GomezLus Centelles M.L., Prieto J.P. Postantibiotic sub-MIC effect of meropenem on Escherichia coli and Staphylococcus aureus. J Chemother 1995; 7 (Suppl. 4):12-4.
7.
Nadler H.L., Pitkin D.H., Sheikh W. The postantibiotic effect of meropenem and imipenem on selected bacteria. J Antimicrob Chemother 1989; 24 (Suppl. A): 225-31.
8.
Majcherczyk P.A., Livermore D.M. Penicillin-binding protein (PBP) 2 and the post-antibiotic effect of carbapenems. J Antimicrob Chemother 1990; 26:593-4.
9.
Maggiolo F., Taras A., Frontespezi S., Legnani M.C., Silanos M.A., Pravettoni G., Suter F. Pharmacodynamic effects of subinhibitory concentrations of imipenem on Pseudomonas aeruginosa in an in vitro dynamic model. Antimicrob Agents Chemother 1994; 38:1416-8.
10.
Bowker K.E., Holt H.A., Reeves D.S., MacGowan A.P. Bactericidal activity, post antibiotic effect and modified controlled effective regrowth time of meropenem at high concentrations. J Antimicrob Chemother 1996; 38:1055-60.
12.
Nilsson-Ehle I., Hutchison M., Haworth S.J., Norrby S.R. Pharmacokinetics of meropenem compared to imipenemcilastatin in young, healthy males. Eur J Clin Microbiol Infect Dis 1991; 10:85-8.
13.
Dreetz M., Hamacher J., Eller J., Borner K., Koeppe P., Schaberg T., Lode H. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother 1996; 40:105-9.
14.
Norrby S. Carbapenems. Med Clin North Am 1995; 79:745-59.
15.
Wise R., Logan M., Cooper M., Ashby J.P., Andrews J.M. Meropenem pharmacokinetics and penetration into an inflammatory exudate. Antimicrob Agents Chemother 1990; 34:1515-7.
16.
Colardyn F., Faulkner K.L. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. 1996; 38:523-37.
17.
Garau J., Blanquer J., Cobo L., et al. Prospective, randomized, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis 1997; 16:789-96.
18.
Verwaest C., Belgian Multicenter Study Group. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care units. Eur J Clin Microbiol Infect Dis 2000; 6:294-302.